The landscape of oncology is shifting from a one-size-fits-all approach toward a highly surgical precision, particularly in how we manage HPV-associated throat cancers. Ivan Kairatov, a veteran in the biopharmaceutical sector with a career dedicated to navigating the intersection of clinical research and technological innovation, has seen this evolution firsthand. With the recent findings from The Ohio State University Comprehensive Cancer Center, there is a renewed focus on using circulating tumor DNA to refine how we treat oropharyngeal malignancies. Our discussion centers on the biological nuances of liquid biopsies, the challenge of balancing survival with long-term patient well-being, and the sophisticated data models required to move these laboratory breakthroughs into the clinic. We explore how tumor biology and even kidney function play surprising roles in how we monitor disease, ultimately painting a picture of a future where therapy is as unique as the patient’s own genetic signature.
Standard radiation and chemotherapy for throat cancer often lead to long-term issues like difficulty swallowing or chronic dry mouth. How are you currently balancing aggressive treatment with a patient’s quality of life, and what specific clinical signs suggest a patient might be a candidate for reduced therapy?
In the current clinical environment, we are acutely aware that while more than 90% of throat cancer cases are now linked to HPV and respond remarkably well to treatment, the price of that success is often a lifetime of debilitating side effects. Patients frequently emerge from aggressive cycles of radiation and chemotherapy only to face a “new normal” defined by chronic dry mouth, severe taste changes, and even the onset of hypothyroidism or sleep apnea. To balance this, we are increasingly looking at the biological activity of the tumor itself rather than just its size; specifically, we monitor how the circulating tumor HPV DNA, or ctDNA, reacts in the earliest stages of intervention. If a patient shows a rapid clearance of this DNA or presents with early-stage tonsil involvement without aggressive pathologic risk factors, they become primary candidates for de-escalation studies. The goal is to move away from the heavy-handed approach of the past and instead use these molecular signals to dial back the intensity, ensuring that a “cure” does not come at the cost of the patient’s ability to enjoy a meal or sleep through the night.
Pre-treatment levels of circulating tumor HPV DNA are often influenced by both tumor biology and a patient’s kidney function. How do these variables complicate the interpretation of blood test results, and what adjustments are necessary to ensure the assessment remains accurate for individual risk profiling?
Interpreting pre-treatment ctDNA is far more complex than simply looking for a “positive” or “negative” result because the blood is a dynamic environment influenced by the body’s overall health. In our recent observations of 104 adult patients, it became clear that the sheer volume of tumor DNA in the bloodstream isn’t just a reflection of the cancer’s size—it is also heavily modulated by how well the kidneys are filtering these fragments. If a patient has slightly impaired renal function, their baseline ctDNA might appear artificially elevated, potentially leading a clinician to believe the cancer is more aggressive or widespread than it truly is. To ensure accuracy, we must normalize these biomarker readings against the patient’s glomerular filtration rate and other metabolic indicators to create a true “baseline.” This adjustment allows us to distinguish between a “leaky” tumor that sheds DNA heavily and a physiological backup caused by the body’s inability to clear those markers, which is vital for setting an accurate starting point for any surgical or therapeutic plan.
Post-operative blood tests reflect both potential residual cancer and baseline tumor DNA levels, meaning a negative result isn’t a total guarantee of being cancer-free. How do you integrate these findings with pathology reports to decide on further treatment, and what is your step-by-step surveillance protocol?
The post-operative window is a critical period of “molecular transition,” where we tested 74 of our patients to see how their DNA levels dropped following surgery. We have learned that a negative ctDNA test in this phase, while encouraging, must be viewed with a healthy dose of skepticism; it doesn’t always mean every microscopic cell is gone, as the test sensitivity has its limits. Consequently, we never look at the blood test in a vacuum, but rather weave it together with the traditional pathology reports that detail margin status and lymph node involvement. Our protocol involves taking that post-surgical blood draw and comparing it against the physical tissue findings; if the pathology shows high-risk features but the blood test is negative, we still lean toward adjuvant radiation to be safe. Conversely, if both the pathology and the ctDNA are clear, we can begin to have very real conversations about reducing the intensity of follow-up treatments, using serial blood draws every few months as a high-tech “smoke detector” to catch any early recurrence before it becomes visible on a scan.
More than 22,000 people are diagnosed with HPV-associated throat cancer annually, with a significantly higher prevalence in men. Considering many cases involve early-stage tonsil tumors, how are diagnostic approaches evolving to catch these sooner? Could you share an anecdote where early biomarker detection altered a patient’s outcome?
The demographic shift in this disease is striking, with the majority of the 22,000 annual cases occurring in men—a trend reflected in our study where 84 of the 104 participants were male. Diagnostic approaches are moving toward the “liquid biopsy” because these tonsil tumors can be notoriously difficult to spot during a standard physical exam until they have already spread to the lymph nodes. I recall a case where a patient presented with very vague symptoms—just a slight persistent throat irritation—that many might have dismissed as a seasonal allergy or minor infection. However, a preliminary screening for circulating HPV DNA showed a definitive spike, which prompted a much more intensive, targeted imaging search that located a tiny, sub-centimeter lesion tucked deep within the tonsillar crypt. Because we caught it at that nearly invisible stage, the surgical team was able to perform a minimally invasive resection, and the patient avoided the grueling months of chemotherapy that would have been mandatory had the cancer progressed just a few months longer.
Developing multifactorial risk models involves combining blood-based biomarker data with traditional clinical and pathologic risk factors. What are the primary hurdles in creating these comprehensive models, and how do you envision this shifting the standard of care for head and neck oncology in the coming years?
The primary hurdle in building these multifactorial models is the sheer noise within the data; we are trying to harmonize the “analog” world of traditional pathology—like the physical appearance of cells under a microscope—with the “digital” precision of genomic DNA counts. To make this work, we need massive, longitudinal datasets like the one we’ve been compiling from September 2021 through April 2025 to understand how these variables interact over time. We also face the challenge of sensitivity, as we need to ensure the test can detect even the faintest whisper of residual disease without triggering false alarms that lead to unnecessary anxiety or over-treatment. In the coming years, I envision a standard of care where a patient’s treatment plan is recalculated in real-time; instead of a fixed six-week block of radiation, a patient might have their “dose” adjusted weekly based on how fast their ctDNA levels are falling. This would transform head and neck oncology from a discipline of endurance into one of agile, data-driven precision, where the intensity of the cure is perfectly calibrated to the presence of the disease.
What is your forecast for HPV-associated throat cancer?
I believe we are on the precipice of a “silent revolution” in how we manage this disease, where the focus will shift entirely from survival rates—which are already quite high—to the preservation of the human experience. Within the next decade, I forecast that the standard “heavy” protocols of surgery followed by blunt-force radiation will be replaced by “adaptive therapy” driven by the very biomarkers we are studying today at Ohio State. We will see a significant reduction in the 22,000 annual patients suffering from long-term side effects like swallowing dysfunction, as liquid biopsies allow us to identify the “low-risk” majority who can be cured with far less toxic interventions. Ultimately, HPV-associated throat cancer will become a model for the rest of oncology, proving that by listening to the molecular signals in a patient’s blood, we can achieve the ultimate goal of medicine: curing the person without breaking the patient.
